|
Market Closed -
Nasdaq
16:00:00 2026-09-25 EDT
|
5-day change | 1st Jan Change | ||
| 11.18 USD | -0.36% |
|
-8.36% | +83.88% |
Company Valuation: Silence Therapeutics plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 528 | 454.3 | 527.3 | 259.5 | 213.4 | 508.4 | - | - |
| Change | - | -13.96% | 16.08% | -50.8% | -17.76% | 138.26% | - | - |
| Enterprise Value (EV) 1 | 454.5 | 454.3 | 473.6 | 163.4 | 149.5 | 375.3 | 334.4 | 279.3 |
| Change | - | -0.04% | 4.24% | -65.49% | -8.53% | 151.03% | -10.91% | -16.46% |
| P/E | -13.7x | -9.99x | -11.6x | -6.95x | -3.22x | -21x | -16.9x | -13.8x |
| PBR | - | - | 29.5x | -7.12x | 13.8x | 11.2x | 7.5x | 5.98x |
| PEG | - | 0.8x | 4.94x | 0.2x | -0x | 0.3x | -0.7x | -0.6x |
| Capitalization / Revenue | 42.5x | 26x | 20.8x | 7.57x | 510x | 1,577x | 677x | 2,976x |
| EV / Revenue | 36.6x | 26x | 18.7x | 4.77x | 357x | 1,164x | 445x | 1,635x |
| EV / EBITDA | -10x | -9.44x | -9.64x | -3.29x | -2.2x | -8.42x | -5.62x | -3.65x |
| EV / EBIT | -9.92x | -9.35x | -9.55x | -3.26x | -2.19x | -8.42x | -4.79x | -3.26x |
| EV / FCF | 419x | -9.96x | -10.4x | -3.04x | -3x | -11.3x | -4.85x | -3.2x |
| FCF Yield | 0.24% | -10% | -9.63% | -32.9% | -33.4% | -8.86% | -20.6% | -31.2% |
| Dividend per Share 3 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 3 | -1.742 | -1.527 | -1.491 | -0.99 | -1.89 | -0.532 | -0.662 | -0.81 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 12.42 | 17.5 | 25.38 | 34.27 | 0.4183 | 0.3224 | 0.7505 | 0.1708 |
| EBITDA 1 | -45.39 | -48.11 | -49.11 | -49.69 | -68.06 | -44.59 | -59.51 | -76.58 |
| EBIT 1 | -45.81 | -48.59 | -49.6 | -50.16 | -68.16 | -44.6 | -69.74 | -85.56 |
| Net income 1 | -39.41 | -40.49 | -43.27 | -35.89 | -66.32 | -42.14 | -71.01 | -87.39 |
| Net Debt 1 | -73.54 | - | -53.76 | -96.03 | -63.87 | -133.1 | -174 | -229.1 |
| Reference price 3 | 23.89 | 15.25 | 17.37 | 6.88 | 6.08 | 11.18 | 11.18 | 11.18 |
| Nbr of stocks (in thousands) | 29,928 | 35,893 | 38,670 | 47,215 | 47,234 | 60,209 | - | - |
| Announcement Date | 3/17/22 | 3/15/23 | 3/13/24 | 2/27/25 | 3/5/26 | - | - | - |
1USD in Million2GBP in Million3USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -21.02x | 1163.95x | -8.42x | - | 673M | |
| 33.26x | 5.97x | 17.88x | 0.98% | 47.97B | |
| 34.82x | 3.35x | 14.46x | -.--% | 44.5B | |
| -21.07x | 227.64x | -22.77x | -.--% | 43.93B | |
| 47.27x | 5.47x | 29.96x | -.--% | 41.03B | |
| 26.85x | 7.74x | 19.93x | 0.42% | 29.85B | |
| 35.19x | 5.78x | 26.24x | -.--% | 17.27B | |
| -61.04x | 9.99x | 243.78x | -.--% | 15.34B | |
| 25.79x | 2.21x | 9.6x | 1.04% | 15.3B | |
| Average | 11.12x | 159.12x | 36.74x | 0.3% | 28.43B | |
| Weighted average by Cap. | 19.59x | 46.75x | 26.02x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SLN Stock
- Valuation Silence Therapeutics plc
Select your edition
All financial news and data tailored to specific country editions
